
Pulmonary Fibrosis
Latest Content
Video Series

Latest Videos
Shorts








Podcasts
More News

AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.

FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs

Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.

Yet Khor discusses why a 20% CT emphysema threshold, not spirometry alone, best identifies CPFE and predicts outcomes in fibrotic ILD.

A Chest study of 1576 patients finds a 20% emphysema threshold best predicts survival and lung function decline in fibrotic ILD.

A 3-cohort study finds CC16 levels flag airway remodeling and fibrosis-like lung damage up to 3 years after severe COVID-19.

Polygenic risk scores show promise for idiopathic pulmonary fibrosis (IPF), though clinical implementation challenges remain, said David Zhang, MD.

Large biobank study suggests a polygenic risk score may improve prediction of idiopathic pulmonary fibrosis diagnosis and outcomes.

Patients with familial pulmonary fibrosis had faster FVC decline and were more likely to have a UIP pattern, supporting family history as a prognostic tool.

Pooled TETON trial data showed inhaled treprostinil preserved lung function in IPF, supporting an FDA submission planned for 2026.

CHMP issued a positive opinion for nerandomilast in IPF and PPF, bringing the therapy closer to European Union approval.

Invited commentaries on the CORAL trial praise nalbuphine's potential in IPF cough while raising questions about safety and durability.

Yet Khor, MD, PhD, discusses ILD care disparities, telehealth, trial awareness, and shared care strategies.

Patients with IPF hospitalized for CDI had higher mortality, longer stays, and greater costs.

TETON-1 data show inhaled treprostinil improves FVC and reduces worsening in IPF, supporting a potential new treatment and combo strategy.

Nerandomilast may represent a meaningful addition to the treatment arsenal, offering patients and clinicians a new option for pulmonary fibrosis.

Explore frequently asked questions on IPF therapies, including approved drugs, emerging treatments, and approaches to slow fibrosis.

Deupirfenidone received orphan drug designation from the FDA and European Commission for idiopathic pulmonary fibrosis treatment.













